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Abstract: The major challenge in the treatment of patients with advanced lethal prostate cancer
is therapeutic resistance to androgen-deprivation therapy (ADT) and chemotherapy. Overriding
this resistance requires understanding of the driving mechanisms of the tumor microenvironment,
not just the androgen receptor (AR)-signaling cascade, that facilitate therapeutic resistance in
order to identify new drug targets. The tumor microenvironment enables key signaling pathways
promoting cancer cell survival and invasion via resistance to anoikis. In particular, the process of
epithelial-mesenchymal-transition (EMT), directed by transforming growth factor-β (TGF-β), confers
stem cell properties and acquisition of a migratory and invasive phenotype via resistance to anoikis.
Our lead agent DZ-50 may have a potentially high efficacy in advanced metastatic castration resistant
prostate cancer (mCRPC) by eliciting an anoikis-driven therapeutic response. The plasticity of
differentiated prostate tumor gland epithelium allows cells to de-differentiate into mesenchymal cells
via EMT and re-differentiate via reversal to mesenchymal epithelial transition (MET) during tumor
progression. A characteristic feature of EMT landscape is loss of E-cadherin, causing adherens junction
breakdown, which circumvents anoikis, promoting metastasis and chemoresistance. The targetable
interactions between androgens/AR and TGF-β signaling are being pursued towards optimized
therapeutic regimens for the treatment of mCRPC. In this review, we discuss the recent evidence on
targeting the EMT-MET dynamic interconversions to overcome therapeutic resistance in patients
with recurrent therapeutically resistant prostate cancer. Exploitation of the phenotypic landscape
and metabolic changes that characterize the prostate tumor microenvironment in advanced prostate
cancer and consequential impact in conferring treatment resistance are also considered in the context
of biomarker discovery.
Keywords: epithelial plasticity; androgen receptor; tumor landscape; metabolic changes
1. Introduction
Prostate cancer is the most frequently diagnosed cancer and the third leading cause of cancer
deaths in males with an estimated 29,430 deaths in the United States for 2018, behind only digestive
system and respiratory system cancers. There is an estimated incidence of 164,690 cases of prostate
cancers in the United States for 2018 [1]. These cases account for approximately 19.2% of all estimated
new cases of cancer in males in the United States. The incidence trend of prostate cancer between
2004 and 2013 showed a significant decrease of −4.8%, and a −8.6% change between 2009 and 2013.
These averages are greater in magnitude than the trends in all site cancers for males of −1.6% and
−2.9%, respectively [1]. The five-year survival for patients with non-metastatic prostate cancer is 98.9%
(measure between 2005 and 2011) but patients with metastatic prostate cancer on initial diagnosis (4%
of prostate cancer patients on diagnosis) had only a 28.2% five-year survival rate [1].
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Almost all cases of patients with prostate cancer will progress to castration resistance, indicated
by increasing serum levels of prostate specific antigen (PSA) despite castrate levels of testosterone
and progress to metastases [2]. 10% to 20% of prostate cancers progress to castration resistant prostate
cancer (CRPC) within 5 years of diagnosis, and 84% of newly diagnosed CRPC have metastases [2,3].
The median survival of patients following diagnosis of castration resistance ranges between 15 and
36 months [4]. Epidemiologic profiling of CRPC has been challenging to determine due to the
lack of standardized diagnostic models, reporting methods for CRPC, and inconsistent terminology
(castration-resistant, hormone refractory, and androgen independent are all used to describe CRPC).
ICD-10 codes indicating CRPC were published for “hormone sensitivity status” and “rising PSA
following treatment for malignant neoplasm of the prostate” in October of 2016 and these data may
contribute to longitudinal epidemiologic information on CRPC. The estimated incidence of mCRPC
in 2009 is 36,100 and for 2020 projected to 42,970. All-cause prostate cancer mortality from the same
model was estimated at 219,360 for 2020 with mCRPC accounting for 19.5% (approximately 42,680)
of these deaths [2]. Improvements to prostate cancer standards of care and 5-year survival following
prostate cancer diagnosis have likely increased incidence of CRPC.
2. Standards of Care for Diagnosis and Treatment
2.1. Diagnosis of Prostate Cancer
Prostate cancer screening includes a digital rectal exam or a serum PSA test. Conventionally,
4.0 ng/mL or lower serum PSA was considered “normal”, and higher values indicate an increased risk
of prostate cancer. Randomized trials of the PSA screening method have demonstrated comparable
rates of prostate cancer among patients with less than and greater than 4 ng/mL [5]. Additionally,
serum PSA may also fluctuate with prostatitis, urinary tract infections, previous prostate biopsy or
surgery, and some drugs, including finasteride and dutasteride which lower serum PSA [6]. As a
result, the National Cancer Institute recommends PSA screening be used based on patient risk factors
and age. Prognostic scoring of prostate tumor biopsy specimens is evaluated by the Gleason system.
Gleason scores range from 2 to 10 with higher scores representing a worse prognosis [7]. Scoring
requires a biopsy of prostate tissue and is based on 5 different distinct structural phenotypes graded
1–5. A grade is assigned to the most prominent cell morphology, then added to the next highest
grade structural phenotype (1–5) seen on histology. In a 2005 Gleason grading consensus conference
it was decided that a Gleason score of 2 should be referred to as pre-cancerous adenosis, and that
low-grade cancerous scores range from 3 to 4 [8]. The recent efforts towards personalized markers
of prostate cancer diagnosis and prognosis, have established that Gleason score is highly associated
with individual markers of cancer progression that help with clinical decision towards a course of
treatment [8,9].
Additionally, the prostate intraepithelial neoplasia (PIN) phenotypes is assigned to a
pre-cancerous phenotype characterized by prominent epithelial nucleoli in an otherwise normal
glandular duct. High-grade PIN (HGPIN) is characterized by four distinct morphological patterns
and is an indicator of risk for progression to malignancy [10–12]. Both Gleason scores and HGPIN
markers are associated with similar genetic markers and suggest that genotyping of prostate cells with
precancerous phenotypes may aid in early intervention and prevention of an invasive phenotype [13].
HGPIN prostate epithelium has been characterized by increased nearby microvasculature density
when compared to normal glandular epithelium, suggesting the significance of angiogenesis in the
development of premalignant HGPIN phenotype [12].
2.2. Treatment Strategies of Metastatic Prostate Cancer
Exploitation of the androgen sensitivity of prostate cancers for the clinical benefit of patients with
prostate cancer was first defined by Charles Huggins et al. in 1941, in a classical study that showed a
relationship between castration-induced androgen depletion and regression of clinical symptoms [14].
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Mechanistically, the androgen receptor (AR) will dimerize and increase transcriptional activity and
promote prostate epithelial proliferation when bound by testosterone or dihydrotestosterone (DHT) in
the prostate. Testosterone is enzymatically converted to DHT intracellularly by 5-α reductase enzyme
activity, resulting in higher circulating serum testosterone and DHT accumulation in tissues [15]. DHT
binding of AR results in a 10-fold increase in transcriptional activity when compared to testosterone
binding of AR [16].
Castration-induced androgen deprivation therapy (ADT) inhibits the action of testosterone
and DHT on the AR signaling axis by keeping total serum testosterone below 50 ng/dL. ADT is
the first-line suggested therapy for hormone naïve prostate cancer with or without metastases [17].
Estrogen therapy resulted in cardiovascular toxicity and is not indicated for use at high doses [18].
Gonadotropin-releasing hormone (GnRH) agonist therapies provided a less-toxic, reversible alternative
to orchiectomy and estrogen therapy. GnRH agonist and AR antagonist ADT remain the first-line
treatment for prostate cancers, with median response duration of only 18 months [3]. The relatively
short response to ADT of approximately 1.5 years provides a clinical challenge to expand the duration
of efficacy for first line prostate cancer therapies. The indicated first line therapies fail to increase 5-year
year disease-free survival and at present, provide only a temporary patch that ultimately results in
progression the resistance.
Among patients who initially present with androgen-sensitive prostate tumors that have already
progressed to metastases, the first line therapy is ADT. Clinically, for patients with non-metastatic
CRPC, a rapidly increasing PSA despite ADT is a known risk factor for metastases [16,19].
Hormone-naïve prostate cancer with markers of early metastasis, but lacking symptomatic and
radiologic evidence of metastasis, the indicated course of clinical action therapy remains ADT with
active surveillance. Second line treatments are indicated for ADT resistant mCRPC and include
chemotherapy, second-line hormones and immunotherapy.
Docetaxel with prednisone is the indicated chemotherapeutic treatment for chemotherapy-naïve
mCRPC patients. Docetaxel was approved by the FDA in 2004 as a combination drug with prednisone
demonstrating a 2.5-month median survival benefit (total 19.2 months post-castration resistance)
in CRPC patients being treated with mitoxantrone and prednisone (MP), the previous standard of
care [20,21]. Docetaxel is a taxane that functions by inhibiting microtubule formation and blocking
cell division, as well as disruption of AR signaling by inhibiting androgen-dependent AR nuclear
translocation. Cabazitaxel, the second–line taxane chemotherapy has a similar mechanism of action
and is indicated for docetaxel-resistant CRPC and demonstrates a 2.4-month median survival benefit
(15.1 months total) when compared to other docetaxel resistant patients treated with MP [22,23].
Cabazitaxel is characteristically more toxic than MP and there is significantly larger risk of drug-related
deaths, neutropenia, diarrhea, and febrile neutropenia when compared to MP [2,24].
The second-generation antiandrogens may prolong survival in patients with chemotherapy naïve
mCRPC and docetaxel pretreated populations [3]. Abiraterone acetate is an androgen synthesis
inhibitor that functions by irreversibly inhibiting CYP17A and is administered with prednisone.
A double-blind placebo-controlled phase 3 study administered abiraterone acetate plus prednisone
to patients with mCRPC that showed tumor progression after docetaxel treatment. Median survival
for the abiraterone group was 4.6 months longer than the placebo in patients with mCRPC [2,3].
Enzalutamide is another androgen signaling inhibitor indicated for patients with mCRPC that
prolonged survival in patients with mCRPC by a median of 4.8 months when compared to a
placebo [25]. Enzalutamide competitively binds the testosterone/DHT receptor on AR, blocking
translocation of AR to the nucleus, as well as DNA-binding of nuclear AR [26].
A newly FDA approved therapy, apalutamide, is indicated for patients who have CRPC, without
radiographic or clinical signs of metastases. Apalutamide is a non-steroidal competitive inhibitor of
AR used concurrently with ADT for patients with high-metastatic risk CRPC (PSA of ≥8 ng/mL or
PSA doubling time of ≤10 months). Apalutamide recently demonstrated a 2.5-fold increase in median
metastases-free survival when compared to placebo in a phase-3 trial (40.5 months for the apalutamide
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group versus 16.2 months for the placebo group) [27]. Like enzalutamide, apalutamide competitively
binds the testosterone/DHT receptor of AR, therefore preventing translocation and DNA-binding of
AR [28]. These results indicate that metastases may be postponed and may potentially eliminate the
need to passively survey tumors that are “silently” progressing to aggressive metastases and provides
clinicians an option for treatment prior to metastases.
Cellular immunotherapy is indicated for asymptomatic mCRPC and utilizes host immune
system to stimulate a T-cell response against the prostate cancer. The process involves isolating
patient peripheral blood antigen-presenting mononuclear cells and exposing the cells to recombinant
prostatic acid phosphatase (PAP) antigen in vitro in the presence of granulocyte colony-macrophage
stimulating factor (GM-CSF). PAP is commonly expressed in prostate cancers of all Gleason scores (GS),
but decreases as score increases, one study showed 100% immunoreactivity among GS 6 and 7 tumors
but decreased to 61% and 78.2% among GS 9 and 10 tumors, respectively. Therefore, PAP was chosen
as the antigenic immune stimulator for sipuleucel-T, the first cellular immunotherapy approved by
the FDA in 2010 [28]. The sipuleucel-T autologous PAP antigen-specific monocytes are infused three
times in 2-week intervals and have shown a 33% reduction in risk of death with a 4.3-month median
increase in survival time when compared to mCRPC patients receiving placebo [11].
3. Contributors to Therapeutic Resistance in Advanced Prostate Cancer
3.1. The Androgen Receptor (AR)
Patients with CRPC commonly have AR gain-of-function mutations that permit tumor cell growth
in the absence or near-absence of androgens by increased ligand responsiveness, AR overexpression,
and constitutive activation of unbound AR, resulting in an androgen signaling axis that is not mitigated
by therapeutic repression of androgens [3,29]. In vitro studies of castration resistant prostate cancer
cell lines displayed mutations of the AR ligand binding domain (H∆Y874, T∆A877) that may increase
tumor responsiveness to hydrophobic biomolecules including the original AR ligands testosterone and
DHT, as well as novel ligands such as β-estradiol that entirely circumvent the tumor dependence on
androgens. In vitro CRPC cells have also demonstrated increased AR expression, a characteristic found
in 30% of clinical CRPC cases, or expression of constitutively active AR [16,30,31]. AR transcriptional
coregulatory proteins (co-activators/co-repressors) also play a role in the progression to therapeutic
resistance. In vitro studies have shown that prostate cancer cells grown in the presence of high doses
of DHT displayed at least two-fold increases in the transcriptional activity of the genes AIB1, CBP,
MAK, BRCA1 [31–33]. AIB1 (Amplified in Breast Cancer 1) acts as a steroid receptor coactivator and
is commonly overexpressed in primary breast carcinomas [33]. MAK (Male Germ Cell-Associated
Kinase) acts as a coactivator of AR and an androgen-independent intracellular increase of MAK in
prostate cancers may mediate androgen independence [34]. CBP (CREB binding protein) is another
transcription factor that may increase the AR expression to promote castration resistance. Breast Cancer
Protein 1 (BRCA1) is a well-known hormonally induced AR coactivator. Additionally, β-catenin, a
protein associated with cell-cell adhesion as a part of E-cadherin, displayed decreased expression in cell
lines with induced AR overexpression [35]. Loss of β-catenin expression is a potential contributor to
metastases in CRPC by reducing cell-cell adhesions of de-differentiated epithelial cells and promotion
of EMT [33].
3.2. Tumor Suppressor Action
A wealth of evidence has fueled the significance of loss of tumor suppressor genes such as p53
and pTEN in prostate cancer initiation, progression and therapeutic resistance in advanced disease [36].
Commonly associated defects in tumor suppression and CRPC are p53, pTEN, ETS-related gene (ERG),
and BCL-2. p53 protein has a well-defined role in cell-cycle maintenance in response to stressors such
as DNA damage and oncogene expression, and a role in AR expression. p53 responds to intracellular
stressors such as DNA breaks, UV radiation induced lesions, and hyper-proliferation by acting as
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a transcription factor for p21, which inhibits cyclin-dependent kinase (CDK) and arresting the cell
in G1 [37]. Other functions of p53 include pro-apoptotic signaling, senescence, DNA repair, and
differentiation, but the majority of p53 cell responses end in apoptosis [38].
Loss of pTEN progresses prostate cancers to CRPC by activation of the phosphatidylinositol
3-kinase (PI3K)/protein kinase-B (AKT) pathway. In normal cells PI3K activates phosphatidylinositol
3,4,5-triphosphate (PIP3) via phosphorylation, and PIP3 is degraded by pTEN to maintain homeostasis.
In cases of partial or complete pTEN loss, undegraded PIP3 will downstream activate AKT, resulting
in Bcl-2-associated death promotor (BAD) protein and caspase 9 inhibition, ultimately decreasing
apoptosis, inhibition of forkhead box protein O4 (AFX) transcription factor, reducing expression of cell
cycle regulator p27, and activate FKBP-12-rapamycin associated protein (FRAP)/mammalian target
of rapamycin (mTOR) which induce translation of cyclin D1 to promote cell cycle progression [38].
Increased AKT expression is common in prostate cancers and is associated with poor prognosis,
therapeutic resistance, and serves as an independent biochemical indicator of recurrence in prostate
cancers [39]. Homozygous and heterozygous loss of the pTEN gene has been reported in up to 13–15%
of local prostate tumors, and 30–39% of metastatic cases [10]. In one study, almost half of CRPC
patients presented with partial or complete pTEN loss [40–42]. In a study of ERG and multi-phase
prostate cancers (ADT treated cancers, CRPC, and mCRPC), expression was associated with loss of
pTEN in prostatectomy and local CRPC patients. Loss of pTEN in the cohort was only associated with
shorter progression-free survival only in ERG expressing patients, indicating the association between
the two transcription factors and tumor progression. Most patients also displayed loss of p53 [43].
A recent study by Yang et al. demonstrated that loss of pTEN in human prostate cancer cells promotes
activation of an AKT-runt related transcription factor 2 (Runx2) signaling axis that induces expression
of steroidogenesis genes CYP11A1, CYP17A1, and intratumoral androgen synthesis [44]. Furthermore,
it was established that pTEN null mice were prone to augmented intratumoral steroidogenesis, as well
as microenvironment remodeling. The effects of pTEN loss in mice were diminished in the mice with
heterozygous Runx2 deletion, or treatment with the CYP17A1 inhibitor abiraterone acetate [45].
3.3. Growth Factor Signaling
Transforming Growth Factor-β (TGF-β): TGF-β is an intriguing cytokine with bifunctional roles
in the regulation of the normal prostate growth, balancing the signaling interactions within the
microenvironment, acting as tumor suppressor via the apoptosis induction in the early stages of
tumorigenesis and switching to a metastasis promoter via effects on epithelial-mesenchymal transition
(EMT) during tumor progression to metastasis. In normal prostate epithelium TGF-β largely signals
through gene expression regulation and controls cell cycle and microenvironment through both
Smad protein family (SMAD) and non-SMAD signaling pathways [45]. The first step in SMAD
signaling is TGF-β binding to type II TGF-β receptor (TGF-βRII), a receptor with constitutively
active serine/threonine kinase activity, and the ligand-receptor complexes transphosphorylate type
I TGF-β receptors (TGF-βRI), ultimately forming a heterotetramer. Activated TGF-βRI molecules
activate SMAD mediators via phosphorylation. The phosphorylated SMAD molecules complex with
co-factors and travel to the nucleus to induce transcriptional changes. SMAD signaling can regulate
transcriptional output of active genes and activate chromatin-repressed gene, this pathway is illustrated
on Figure 1 [46,47]. TGF-βRIII is a third receptor type that acts as a co-receptor for TGF-β by binding
G alpha interacting protein (GAIP) at the cell membrane and increasing binding affinity of TGF-β2
for the TGF-βR [48,49]. In healthy prostate or early prostate cancer, the TGF-β-SMAD signaling
activates downstream apoptosis and inhibits cellular proliferation. Non-SMAD signaling by TGF-β
leads to down regulation of c-Myc oncogene, resulting in upregulation of CDK inhibitors. c-Myc is
a transcription factor that promotes cell growth and proliferation [50,51]. c-Myc downregulation by
TGF-β is a key step in the inactivation of G1 CDK proteins driving cell proliferation. In particular,
TGF-β induces expression of p15ink4b (p15), a cyclin-dependent kinase 4 inhibitor tumor suppressor
Int. J. Mol. Sci. 2018, 19, 904 6 of 19
protein, that functions to induce dissociation of cyclin-D1 from CDK and prevention of cyclin D1-CDK
complex formation, arresting cells in G1.Int. J. Mol. Sci. 2018, 19, x 6 of 18 
 
 
Figure 1. Signaling pathways contributing to therapeutic resistance in prostate cancer and their 
targetable interactions via EMT to MET interconversions. (A) First and second line antiandrogens 
(abiraterone and enzalutamide) target the AR signaling cascade by reducing testosterone production 
or inhibiting the binding site of AR and subsequent translocation to the nucleus, respectively. (B) 
Mutations in AR signaling promote transcriptional activation despite ADT. (C) TGF-β bi-functionally 
affects cell growth and differentiation through intracellular SMAD and non-SMAD signaling 
including MAP-kinases, loss of E-cadherin, and consequential changes in cell polarity. (D) Distinct 
cell types such as myofibroblasts, CAFs, neuroendocrine (NE) cells, and MDSCs (Myeloid-derived 
suppressor cells) within the microenvironment may navigate therapeutic resistance to antiandrogens 
and taxane chemotherapy by engaging ECM components, growth factors such as TGF-β, VEGF, IGF, 
mitotic promoters, and immune suppression. (E) Loss and gain of E-cadherin serves as a causative 
factor of cell polarity and biomarker of EMT, respectively, under the transcriptional repression of 
SNAI, ZEB1, and Twist-related protein (TWIST) (nuclear transcription factors). Color code: 
Orange/yellow: normal cellular signaling, red: promotors of therapeutic resistance, blue: existing or 
experimental therapies for prostate cancer. 
Insulin-Growth Factor (IGF): IGF also emerges as regulator of EMT upon binding of IGF ligands, 
to IGF receptors IGF-IR and IGF-IIR, and consequential activation of pro-EMT cascade via AKT 
signaling which also upregulates the ZEB protein [52,53]. In a cross-talk mechanism, insulin growth 
factor binding protein-3 (IGFBP3) is involved in IGF signaling regulated by TGF-β. IGFBP3 is 
overexpressed in some cancers, and silenced in others [54,55]. In healthy cells, IGFBP3 regulates IGF-
I and/or IGF–II by binding the molecules and preventing the proliferation cascades initiated by IGF-
R activation. Overexpression of IGFBP3 results in excessive induction of SNAI1, ZEB1, and ZEB2 gene 
transcription [56]. The upregulation of the ZEB protein promotes TGF-β-mediated EMT and enables 
a potential target for overcoming therapeutic resistance. 
Vascular-Endothelial Growth Factor (VEGF): VEGF includes a family of factors, VEGF-A, VEGF-
B, VEGF-C, VEGF-D, and placenta growth factor, that play a distinct role in promoting angiogenesis 
in human malignancies including prostate cancer. VEGF expression is induced by both androgens 
(by non-canonical androgen signaling) and hypoxic environments [54]. In prostate cancer VEGF 
promotes angiogenesis by binding VEGF-R2 (Flk-1) on the vascular endothelial lining to promote 
proliferation and vascular permeability, then organization of nascent capillary tubes into the tumor 
Figure 1. Signaling pathways contributing to therapeutic resistance in prosta e cancer and their
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or inhib ting the binding site of translocation to the nucleus, respectively.
(B) Mutations in i tra scriptional activation despite ADT. (C) TGF-β bi-functionally
affects cell growth and differentiatio thr ugh intracellula SMAD and non-SMAD signaling including
MAP-kinases, loss of E-cadherin, and conseque tial chang s in cell polarity. (D) Distinct cell types
su h as myofibroblasts, CAFs, neuroendocri (NE) cells, and MDSCs (Myeloid-derived suppressor
cells) within th microenviron ent may navigate therapeutic resistanc to antiandrogens and taxan
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prom ters, and immune suppression. (E) Loss and gain of E-cadherin serves as a causative factor of
cell polarity and biomarker of EMT, respectively, under the transcriptional epression of SNAI, ZEB1,
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Insulin-Growth Factor (IGF): IGF also emerges as regulator of EMT upon binding of IGF ligands,
to IGF receptors IGF-IR and IGF-IIR, and consequential activation of pro-EMT cascade via AKT
signaling which also upregulates the ZEB protein [52,53]. In a cross-talk mechanism, insulin growth
factor binding protein-3 (IGFBP3) is involved in IGF signaling regulated by TGF-β. IGFBP3 is
overexpressed in some cancers, and silenced in others [54,55]. In healthy cells, IGFBP3 regulates
IGF-I and/or IGF–II by binding the molecules and preventing the proliferation cascades initiated by
IGF-R activation. Overexpression of IGFBP3 results in excessive induction of SNAI1, ZEB1, and ZEB2
gene transcription [56]. The upregulation of the ZEB protein promotes TGF-β-mediated EMT and
enables a potential target for overcoming therapeutic resistance.
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Vascular-Endothelial Growth Factor (VEGF): VEGF includes a family of factors, VEGF-A, VEGF-B,
VEGF-C, VEGF-D, and placenta growth factor, that play a distinct role in promoting angiogenesis
in human malignancies including prostate cancer. VEGF expression is induced by both androgens
(by non-canonical androgen signaling) and hypoxic environments [54]. In prostate cancer VEGF
promotes angiogenesis by binding VEGF-R2 (Flk-1) on the vascular endothelial lining to promote
proliferation and vascular permeability, then organization of nascent capillary tubes into the tumor
microenvironment via VEGF-R1 (Flt-1) [57–59]. Preclinical studies in androgen-sensitive prostate
cancer xenografts demonstrated that ADT results in a significant of VEGF levels and subsequent
androgen replacement led to upregulation of VEGF expression [60]. VEGF has been the target of
diverse pre-clinical and clinical prostate cancer trials, but the therapeutic response and survival
outcomes remain “a road less taken” to impair advanced disease and impact patients in clinical
practice [59].
3.4. Metabolomic Changes
Genetic changes that progress prostate cancer are known to create unique metabolomic profiles
that may be used as both a diagnostic and prognostic tool, as well as an investigative platform
to identify new metabolic targets for novel therapeutics [61]. Thus, the increase in glycolysis that
leads to increased lactate in most cancer types, known as the “glycolytic switch” or “Warburg effect”
described by Otto Warburg in 1956, is detected in PI3K-driven prostate tumors [62]. Prostate cancer
is metabolomically characterized by increases fatty acid metabolism by fatty acid synthase as well
as an increase fatty acid uptake when compared to healthy prostate cells [63,64]. Further, higher
concentrations of fatty acid synthase mRNA and protein are associated with higher Gleason score and
as an independent predictor of bone metastasis [65–67]. Among TMPRSS2-ERG translocation positive
samples, a characteristic mutation in prostate cancers, fatty acid oxidation related metabolites were
significantly increased, namely cerebronic acid, 2-hydroxybehenic acid, and tricosanoic acid [67,68].
A metabolomic change unique to prostate cancer is the decrease in citrate concentration and
increase in citrate metabolite secretion, mediated by the activation of the enzyme m-aconitase [67].
Zinc acts as an inhibitor of m-aconitase in healthy prostate tissue but decreases in concentration
as the prostate undergoes neoplastic progression [69,70]. Decreases in the cellular concentration of
glucose, mannose, maltose, and maltotriose is concurrent with the decrease in intracellular citrate
and increase in fatty acid metabolites in TMPRSS2-ERG positive tumors, support contribution of
this mutation as a key initiation event in the progression from early pre-malignant phenotypes
such as PIN to malignant prostate cancer [70]. The increased use of fatty acid oxidation and citrate
metabolism increases available ATP in prostate cancer [67] For prostate cancer cells treated with ADT,
the concentrations of lactate and t-choline are expected to decrease, and can be monitored by magnetic
resonance imaging (MRI) to observe any increases despite treatment [71]. In addition to tumor grade
and aggressiveness, metabolomic markers may indicate castration resistance via steroid autogenesis
and/or changes to the androgen signaling axis [72]. Similarly, genomic microRNA (miRNA) profiles
of prostate cancer samples may be a way to take a profile “snapshot” of the metabolic tumor stage
and provide both diagnostic and prognostic information [73]. In particular, the miRNAs miR-96
and miR-21 found in tumor tissues have been identified as indicators of castration resistance that
are positively correlated with tumor grade [74,75]. miRNA changes mediate therapeutic resistance
by a wide set of oncogenic interactions including resistance to apoptosis, inhibition of metabolic
regulatory genes (namely FOXO1), and notably the upregulation of AR in prostate cancer, providing a
direct link to castration resistance [73,76]. Choline phosphate and cysteine both serve as two strong
metabolomic predictors of disease recurrence [72,77,78]. Thus, advanced knowledge of metabolomics
and interpretation of data on metabolic alterations, will lead to the identification of critical metabolites,
as novel signature biomarkers of prostate cancer progression and emergence of therapeutic resistance.
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4. The Impact of Microenvironment on Prostate Tumor Progression
4.1. The Prostate Defines Its Niche in the Microenvironment
The human prostate gland is organized as a lumen surrounded by secretory luminal epithelium,
basal, and neuroendocrine cells. Deep to the basal lamina is a fibromuscular stroma comprised of
fibroblasts, myocytes, endothelial cells, autonomic nerve fibers, immune cells, and a collagen-rich
extracellular matrix (ECM) [79]. In normal prostate tissues, detachment of epithelial cells from the
ECM induces apoptotic cell death through a process called anoikis. The missing epithelial cells are
subsequently replaced by proliferation of endogenous progenitor epithelial cells [80,81]. Anoikis and
stromal factors normally maintain prostatic homeostasis, but in both tumorigenesis and progression to
mCRPC the stroma may promote tumorigenesis through vascularization, anoikis resistant survival
mechanisms, and EMT [82].
As summarized on Figure 1, the functional interactions between cancer-associated fibroblasts
(CAFs), endothelial cells, lymphocytes, and cancer epithelial cells play an important role in progression
to metastases by promoting angiogenesis, repair, and survival as a result of reactivity to TGF-β [83,84].
Stroma reactivity to TGF-β may progress cancer independence from existing prostate vasculature and
establish an independent nutrient and waste exchange via the vascularization of the tumor [46,85].
TGF-β signaling has been shown to stimulate myofibroblast formation from existing prostate
fibroblasts [81]. Myofibroblasts promote tumor progression by repairing and regenerating damaged
tissue, secretion of ECM components such as collagen, and secretion of angiogenesis promoting growth
factors [50].
Neuroendocrine (NED) prostate cancer is a rare clonally proliferated subtype of prostate
adenocarcinoma that is pathologically evident as a small and round undifferentiated
endocrine-paracrine modulating cell type on histologic staining. Clonal proliferation of NED from an
existing prostate cancer is indicated by the prostate cancer specific gene rearrangement TMPRSS2-ERG
in NED prostate cancer cases, that most commonly appears following hormonal therapy of hormone
sensitive prostate cancer [86]. Metastatic NED prostate cancers are characterized by lytic bone lesions,
castration resistance, more rapid progression to metastases, visceral metastases, prostatic enlargement,
and low PSA in metastatic disease [87,88]. Neuroendocrine cells do not express AR or PSA, but have
markers such as chromogranin A, synaptophysin (SYP), and neuron-specific enolase (NSE) that give
NED prostate cancer a distinct biomarker profile and should cause suspicion in cases of metastatic
CRPC with low serum PSA [89]. Genotyping of NED prostate cancer revealed gene amplifications
found significantly higher than non-NED prostate cancer, AURKA and MYCN. AURKA encodes Aurora
kinase A, a serine/threonine kinase involved in mitosis that acts as an oncogene when amplified or
overexpressed. MYCN encodes N-Myc, a transcription factor common to nerve tissue not expressed
in the prostate known to induce expression of Aurora kinase A [90]. Transfection of both AURKA
and MYCN to non-NED prostate cell lines induced expression of the NED-specific markers SYP
and NSE [91]. These results suggest that these genes may be responsible for the progression to the
NED phenotype and provide a potential target for protein or RNA inhibitors to prevent metastases
facilitating tumor microenvironments.
The tumor microenvironment facilitates therapeutic resistance by modification of stromal
components to promote invasion, angiogenesis, and metastases. A characteristic change in the tumor
microenvironment change in metastatic disease is the progression from fibroblasts, an abundant
mesenchymal cell type in the extracellular matrix, to carcinoma-associated stromal cells (CAFs).
Activated CAFs normally secrete alpha-smooth muscle actin (α-SMA) which acts as a chemical
indicator of CAF expression and may play a role in facilitation of EMT of the prostate cancer when CAFs
are constitutively activated in tumor states [88]. Both CAFs and myofibroblasts have repair-centric
activities that promote tumor growth, empowering investigators with new therapeutic platforms
exploiting the inhibition of stromal expression patterns that favor cell differentiation.
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The novel drug DZ-50, a quinazoline derivative generated and characterized in our lab, has
been shown to target the EMT dynamic by promoting the reverse process, MET. Molecular analysis
revealed that DZ-50 causes reversion of EMT to MET in prostate cancer cells by engaging the IGF
signaling [92]. DZ-50 inhibits the IGF signaling pathway by down-regulating gene expression of
specific IGF-binding protein (IGFBP), IGFBP3, and thus antagonizing TGF-β1 mediated stabilizing of
the EMT phenotype [93]. Drug-discovery and repurposing efforts exploit TGF-β signaling effectors
reprogramming phenotypic changes that facilitate tumor progression and treatment resistance.
Targeting the pathways that confer tumor progression by fostering the EMT landscape, will
potentially lead to marginal increases in survival with current standards of care by deconstructing a
microenvironment that sustains therapeutic resistance in individual tumors.
4.2. EMT Landscaping CRPC
The process of epithelial-mesenchymal transition (EMT), was first characterized as the dramatic
extracellular changes that impact epithelial cell polarity and was classified as a distinct phenotypic
pattern of tissue landscape in 1995 [93]. EMT in prostate cancer confers therapeutic resistance, invasive
properties of the tumors and negatively impacts survival in prostate cancer patients [94]. Conversion
of epithelial cells to mesenchymal cells involves profound structural changes, including loss of cell-cell
adhesion, degradation of basement membrane, loss of cell polarity and the acquisition of migratory and
invasive properties [95]. EMT is thus a critical and functionally convenient venue for epithelial-derived
tumors to become invasive and metastasize [94,96]. EMT endows cells with migratory and invasive
properties, induces stem cell properties, prevents apoptosis, and orchestrates metastasis [94].
E-cadherin is essential in the maintenance of epithelial cell-cell adhesions. Loss of E-cadherin
in place of N-cadherin is a key phenomenon common to EMT [83,94,97]. E-cadherin is encoded by
the CDH1 gene on chromosome 16q and maintains cell-cell adhesion by Ca2+ dependent junctions
involving the actin microfilaments α-and β-catenin [98]. Androgen deprivation can potentially
result in E-cadherin transcriptional repression, which is sufficient to confer the EMT phenotype,
and inducing the expression of N-cadherin in androgen-dependent prostate tumors [99,100]. High
N-cadherin/E-cadherin ratio phenotypes are associated with highly invasive cancers. Further,
N-cadherin expression and mRNA levels were increased in androgen-independent tumors in a
castration environment [99,101]. Loss of epithelial-cell markers E-cadherin and β-catenin and gain
of mesenchymal-cell markers N-cadherin and vimentin at the leading edge or invasive front of
solid tumors are linked to metastatic progression [101–103]. These studies indicate N-cadherin
as a potential target for therapeutics to prevent or mitigate metastatic phenotypes. Functionally
it is the signaling activities of mesenchymal cells that facilitate migration and survival in an
anchorage-independent, anoikis-defying mode [104,105]. In prostate cancer cells EMT is induced
by TGF-β and/or androgens, with a threshold AR level determining the phenotypic outcome and
invasive properties [97]. Transcriptional repression of E-cadherin by factors such as SNAI1/SNAI2,
Slug, and TWIST1 block the expression of E-cadherin, disrupting the cell-cell junctions, and allows
β-catenin to enter the nucleus and act as a regulator of EMT [84]. The reverse process of EMT, MET,
provides metastatic CRPC the ability to differentiate into a phenotype that is better suited to colonize
distant sites from the original tumor [96,106,107]. The processes of EMT and MET may occur cyclically
in mCRPC cell lines and the variety of mCRPC phenotypes conferred by MET represents an effective
therapeutic endpoint due to the loss of specific cellular targets [105,108].
4.3. TGF-β: Master Navigator of EMT
In advanced stage high grade prostate tumors, TGF-β serves as an inducer of EMT, by signaling
de-differentiation, cell proliferation, and inhibition of apoptosis by non-SMAD (non-canonical)
signaling pathways [105]. Loss of TGF-βR expression among tumor-stroma in various human
malignancies has been associated with poor clinical outcomes [46,47]. In a retrospective study of
TGF-βRII in colon carcinoma demonstrated that downregulation of the receptor is a strong independent
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prognostic indicator for survival, similar to lymph node metastases and vessel infiltration [109].
In prostate cell lines with induced TGF-βRIII knockdown, there was an associated increase in prostate
CD133 expression [109]. In epithelial cells, the non-canonical TGF-β pathway engages mitogen
activated protein kinase (MAPK), Rho-like GTPase, and PI3K/AKT as signaling effectors [110].
The MAPK signaling mechanism, upon TGF-β recruitment, leads to activation of rapidly accelerated
fibrosarcoma (RAF) kinase/extracellular signal-related kinase (ERK), JNK/p38, and P13K/AKT, a set
of MAPK proteins that bi-functionally induces EMT and blocks SMAD signaling [111]. TGF-β interacts
with the AR signaling axis directly and indirectly to complete its opposing roles in the life cycle of the
cell. In the presence of AR coactivators such as AR-associated protein 55 (ARA-55), AR can inhibit
the up-regulatory effect of TGF-β on SMAD transcriptional activity. This evidence provides proof
of principle that activated AR signaling in prostate tumor cells can counteract the tumor-suppressor
function of TGF-β towards emergence of CRPC.
The reign of TGF-β as a bifunctional controller within the tumor microenvironment is perhaps
most prominent in the late stages of progression to metastases. TGF-β2 is known to mediate
the conversion of naïve prostate fibroblasts to CAFs expressing α-SMA [112]. As mentioned
before, the prostate microenvironment is particularly reactive to TGF-β. Stroma CAFs, endothelial
cells, lymphocytes, and cancer epithelial cells all appear to facilitate angiogenesis in response to
TGF-β [85,113]. siRNA induced AR-knockdown CAFs demonstrated decreased TGF-β expression,
indicating a relationship between the androgen signaling axis and TGF-β [81]. In mouse models
of prostate tumorigenesis driven by aberrant TGF-β1 signaling there is increased collagenous
micronodules, a lesion associated only with cancer and not benign glands [114]. The microRNA family
miR-200 and zinc finger E-box-binding homeobox (ZEB) have been implicated in transcriptionally
regulating the EMT to MET interconversions [115]. ZEB proteins transcriptionally repress E-cadherin
and EMT is a consequence of ZEB overexpression [55]. In cells with hyper-methylated miR-200 loci
demonstrate a stabilized ZEB/miR-200 molecular imbalance and maintaining the EMT phenotype [55].
The increased TGF-β1 secretion in the engineered TWIST overexpression cells correlated with increased
SMAD activity and SMAD2 phosphorylation, an autocrine TGF-β-mediated maintenance mechanism
for mesenchymal phenotypes [116].
5. Targeted Therapies to Overcome Therapeutic Resistance
Bioinformatics-driven studies focus on personalized marker discovery to predict treatment
failure in individual prostate cancer patients. The emerging scenario defines the significance of
cellular stroma microenvironment dynamics towards individualizing therapy with existing treatments,
by acknowledging the stroma influence and co-evolution with cancer, particularly fibroblastic changes
that facilitate the epithelium to de-differentiate [117]. As mentioned before, PSA doubling-time
has been recognized as an indicator for risk of metastases [118]. Overall survival prognostic
models for mCRPC patients that included lactate dehydrogenase (LDH), albumin, hemoglobin, PSA,
and alkaline phosphatase as variables (among other performance markers) are highly predictive of
patient survival [20,21]. Cytokines involved in tumor growth and metastases, interleukin 6 (IL-6)
and tumor necrosis factor-α (TNF-α), are also important serum biomarkers with high prognostic
value in prostate cancer patients [119,120]. Serum IL-6 is significantly increased in patients with
CRPC when compared to values of healthy controls, patients with benign prostatic hyperplasia (BPH),
and localized prostate cancer [121,122]. Patients showed decreased overall survival when serum
values of both IL-6 and TNF-α are found above the 95th percentile values of healthy controls when
compared to prostate cancer patients with values below the cutoff [123]. The use of transcriptomics
and genomics to identify markers such as AR signaling genes, AR splice variants, P13K/AKT pathway
genes, and other housekeeping genes, as well as somatic mutations in FOXA1, SPOP, pTEN, pathogenic
mutations in TP53, and germline mutations in BRCA2 or ATM has been most creative. Genetic testing
on patients may suggest simultaneous regimens of ADT and docetaxel as first-line therapy when
genotypic markers show high-risk profiles in localized tumors [122]. This provides a molecular basis to
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overcome ADT resistance in a subset of CRPC patients harboring AR mutations/variants, modulated
intratumoral steroidogenesis, loss of DNA repair mechanisms, and changes in phenotypic landscape
such as EMT and NED [124,125].
Compelling new insights into the combination strategies of novel AR-signaling inhibitors that
bind the N-terminal domain (NTD) of AR, EPI-001/002, and taxane chemotherapy, have established in
pre-clinical in vivo and in vitro models the synergistic action in the reversal of de-differentiated
EMT phenotypic CRPC to a guided MET phenotype that is more conventionally susceptible to
therapies [88]. As shown on Figure 1, the novel AR-NTD inhibitor sintokamide A (SINT) is effective
in vivo at regressing CRPC xenografts and reducing PSA, with additive effects to EPI due to targetable
interactions between AR-NTD and target STAT3 [126].
Myeloid-derived suppressor cells (MDSCs) play an important role in tumor evasion of the
immune system, and increased MDSCs are correlated with serum PSA and metastases of prostate
cancer [127]. Anti-cancer multikinase inhibitors such as cabozantinib and BEZ235 are targeted at
metastatic-infiltrating CRPC and display minimal activity against tumors. In addition to circulating
MDSCs, regulatory inhibition of cytotoxic T-cells by cytotoxic T-lymphocyte-associated protein 4
(CTLA4) downregulates the immune response by inactivating the cell-mediated immune response.
Therapies such as ipilimumab target the CTLA-4 cascade as an inhibitor of the regulatory cascade.
Trials of ipilimumab therapy in mCRPC have failed to demonstrate efficacy [128,129]; however, in trials
with combination therapies (anti-MDSC and immunomodulatory), patients with either localized
disease or mCRPC demonstrated robust responses [130,131]. These studies support a promising
clinical benefit surrounding the combination regimens of immunomodulatory drugs and anti-MDSCs
as effective in overcoming therapeutic resistance (Figure 1).
The chemo-preventive agent silibinin is used as a preventative therapy for patients with naïve
prostate cancer to impair disease progression to mCRPC. Silibinin inhibits induction of mesenchymal
phenotype (CAFs) and overexpression of α-SMA by blocking TGF-β2 expression [132]. Similarly,
treatment with apigenin, a naturally occurring flavone decreases the TGF-β1 induced expression of
VEGF in mice and reduces the fraction of α-SMA myofibroblasts in ex vivo lung cancer biopsies [85].
The target sites for both silibinin and apigenin are shown on Figure 1. Other therapies including
monoclonal antibody against VEGF, bevacizumab, that reduced tumor volume by targeting tumor
vascularity, failed to demonstrate significant improvement in overall survival for patients already on
taxane chemotherapy with prednisone [113,133].
6. Conclusions
In the year 2018, molecular technology and large data processing provide great new platforms
for understanding to complexity and heterogeneity of prostate tumors and developing strategies to
prevent, postpone, or mitigate the migratory and invasive phenotypes of prostate cancer, beyond
the AR signaling. Exploitation of EMT regulatory proteins as distinct phenotypic markers of tumor
progression, as well as novel therapeutic targets including cellular processes mediated by the TGF-β
non-SMAD signaling family that facilitate a tumor-promoting microenvironment, will lead to precision
diagnosis and optimized combination strategies to impair metastatic and therapeutically resistant
disease. Utilizing the distinct markers that arise from the microenvironment modifiers such as the
neuroendocrine cells or CAFs, may provide a clinical edge to tumor progression provided available
therapeutic targets for the identified stromal pathways. The tumor microenvironment consisting of
myofibroblasts, CAFs, neuroendocrine cells, and MDSCs has been under a low-profile pursuit as
potential therapeutic targets/platforms, despite compelling evidence as to their functional contribution
to the phenotypes driving tumor progression to metastases and emergence of therapeutic resistance
(Figure 1).
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